| Cite this article: |
| SHEN Qianhui,JIA Kang,LIU Yuan,ZHANG Zhixian,MAI Chengxiong,PI Rongbiao,ZHOU Sigui.Research progress of masitinib, an antitumor drug in the treatment of neurodegenerative diseases[J].Journal Of Pharmaceutical Research,2025,44(3):257-264[Click to copy] |
|
| 摘要: |
| 阿尔茨海默病(Alzheimer’s disease,AD)、肌萎缩侧索硬化症(Amyotrophic lateral sclerosis,ALS)和多发性硬化症(Multiple sclerosis,MS)等神经退行性疾病患病人数逐年增加,但仍缺乏确凿有效的治疗药物。马赛替尼最初作为一种口服多靶点酪氨酸激酶抑制剂用于治疗癌症,近来研究发现,其对多种神经退行性疾病表现出潜在的神经保护作用。本文综述了马赛替尼在治疗AD、ALS及MS方面的研究进展。 |
| 关键词: 马赛替尼 阿尔茨海默病 肌萎缩侧索硬化症 多发性硬化症 |
| DOI:10.13506/j.cnki.jpr.2025.03.008 |
| 基金项目:国家自然科学基金项目(No.81671264) |
|
Publication Date:March 25, 2025
|
|
| Research progress of masitinib, an antitumor drug in the treatment of neurodegenerative diseases |
| SHEN Qianhui1,JIA Kang1,LIU Yuan2,ZHANG Zhixian2,MAI Chengxiong3,PI Rongbiao2,ZHOU Sigui1 |
| (1. School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; 2. School of Medicine, Sun Yat-sen University, Shenzhen 518107, China; 3. Department of Food and Health Science, Technological and Higher Education Institute of Hong Kong, Hong Kong SAR 999077, China) |
| Abstract: |
| The prevalence of neurodegenerative diseases such as alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) is increasing annually, yet effective therapeutic drugs remain elusive. Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has recently shown potential neuroprotective effects in various neurological disorders.This review summarizes the research progress of Masitinib in the treatment of AD, ALS and MS. |
| Key words: Masitinib Alzheimer's disease Amyotrophic lateral sclerosis Multiple sclerosis |